Published Date: March, 2016
It was October 20, 2010, when the U.S. Food and Drug Administration asked manufacturers to add new warnings to labeling of gonadotropin-releasing hormone (GnRH) agonists, a class of drugs primarily used to treat men with prostate cancer. The warnings alert patients and their health care professionals to the potential risk of heart disease and diabetes in men treated with these medications.